681821-42-1Relevant articles and documents
Pyrenedione-Catalyzed α-Olefination of Nitriles under Visible-Light Photoredox Conditions
Bains, Amreen K.,Ankit, Yadav,Adhikari, Debashis
, p. 2019 - 2023 (2021)
Herein, we report a combination of pyrenedione (PD) and KOtBu to achieve facile alcohol dehydrogenation under visible-light excitation, where aerobic oxygen is utilized as the terminal oxidant. The resulting carbonyl compound can be easily converted to vinyl nitriles in a single-pot reaction, at 60 °C in 6-8 h. This environmentally benign, organocatalytic approach has distinct advantages over transition-metal-catalyzed α-olefination of nitriles, which often operate at a significantly higher temperature for an extended reaction time.
Manganese-Catalyzed α-Olefination of Nitriles with Secondary Alcohols
Balaraman, Ekambaram,Landge, Vinod G.,Subaramanian, Murugan,Yadav, Vinita
, p. 947 - 954 (2020/01/13)
An expedient catalytic approach for α-olefination of nitriles using secondary alcohols with the liberation of molecular hydrogen and water as the only byproducts is reported. This reaction is catalyzed by a molecularly defined manganese(I) pincer complex and operates in the absence of any hydrogen acceptors. A broad range of substrates including cyclic, acyclic, and benzylic alcohols, as well as various nitrile derivatives, such as arylmethyl and heteroarylmethyl nitriles, are employed in the reaction to provide a diverse range of α-vinyl nitriles in good to excellent yields. Mechanistic studies showed that the reaction proceeds via dehydrogenative pathway and the activation of α(C-H) bond of the alcohol is the rate-determining step.
Imidazoline compounds
-
Page 3, (2008/06/13)
Compounds of formula (I): wherein: R1 represents an optionally substituted heteroaryl group, R2 represents an optionally substituted cycloalkyl group, R3 represents a hydrogen atom or an alkyl group, and R4 and R5 are as defined in the description, and Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.